← Investor PortalInterested in the Company? Request more Information

BT457321

Revolutionizing cancer treatment with a non-invasive, AI-powered therapy designed to enhance effectiveness while eliminating the pain and side effects of traditional treatments. By combining oxygen therapy, peptides, IV-based treatments, and advanced AI diagnostics, it offers a 70% success rate, providing a breakthrough alternative for millions of patients worldwide.
‍
With a $280B market opportunity, growing demand for personalized, less toxic cancer treatments, and early traction in hospital partnerships, the company is positioned to disrupt the oncology space. Its scalable telemedicine model, integration with AI-powered precision medicine, and patent-pending technology offer a first-mover advantage in the next evolution of cancer care.
‍
Now raising $2M to expand clinical adoption, refine its AI diagnostics, and build a world-class team, this is an opportunity to invest in a high-growth biotech transforming how cancer is treated globally.

Overview

  • Industry: Biotech & Oncology Treatment
  • Founded: 2024
  • Location: U.S.-based
  • Core Focus: Developing innovative, non-invasive cancer treatments with AI-driven diagnostics and personalized therapies
  • Technology: Telehealth, oxygen therapy, peptides, IV treatments, and AI-powered predictive analytics
  • Development Stage: AI tool in prototype phase, treatment market-ready
  • Intellectual Property: Provisional patent application in progress
  • Go-To-Market Strategy: Partnerships with hospitals, clinics, telemedicine providers, and patient advocacy groups
  • Funding Required: $2M for expansion, R&D, and commercialization

Problem & Solution

  • The Problem

    →     Cancer remains one of the most significant global health crises, with traditional treatments being expensive, painful, and often ineffective.
    → Current cancer treatments come with severe side effects, and accessibility remains a challenge in many regions.
  • The Solution

    →     A painless, AI-driven cancer treatment with a 70% success rate in early trials.
    → Combination therapy model integrates oxygen therapy, peptides, and IV-based treatments, reducing side effects while enhancing efficacy.
    → AI-powered telemedicine platform for early detection, monitoring, and personalized treatment plans.

Market Potential

  • Target Market: Cancer patients and oncology care providers
  • Market Size:

    → TAM: $280B
    → SAM: $150B
    → SOM: $500M
  • Growth Rate: Oncology market growing at 9.7% CAGR
  • Key Trends:

    → Shift to personalized, non-invasive cancer treatments
    →     AI-powered diagnostics and liquid biopsy advancements
    →     Expansion of immunotherapy and targeted therapies
    →     Increased focus on outpatient and telehealth-based care

Product & Technology

  • Core Offering: Non-invasive cancer treatment combining telehealth, oxygen therapy, peptides, and IV-based therapies.
  • Technology Stack: AI-powered diagnostics leveraging Python, TensorFlow, ChatGPT, and Google Cloud.
  • Current Stage:
    → AI tool in prototype phase
    → Treatment protocols market-ready
  • Intellectual Property: Provisional patent application in progress.
  • Future Development:
    → CRISPR and DNA sequencing integration for personalized tumor analysis.
    → Expansion of AI-driven diagnostics for early-stage cancer detection.

Business Model & Revenue Strategy

  • Revenue Model:
    → $150 per treatment session, or $30,000 for full treatment package.
    → Subscription model for AI-based diagnostics and monitoring.
  • Sales Channels:
    → Hospitals, clinics, telemedicine providers, and group purchasing organizations.
    → Compassionate use and assistance programs to improve accessibility.
    → Medical education outreach to increase adoption among healthcare professionals.
  • Customer Acquisition Strategy:
    → Direct-to-patient marketing, focusing on patient advocacy groups.
    → Digital campaigns targeting proactive patients and caregivers.
  • Customer Retention: Focus on quality-of-life improvements and long-term survivorship benefits.

Traction & Milestones

  • Initial patient trials report a 10/10 satisfaction rate.
  • Signed partnership with a New Orleans hospital for treatment deployment.
  • Launched “Medical Concierge” for sharing research results and treatment progress.
  • Prototype AI diagnostic tool under development.

Financials

  • Current Burn Rate: $10K/month
  • Runway: 1 year (pre-funding)
  • Total Funding to Date: $100K
  • Financial Projections:

    ‍Year 1 Revenue: $100K
    ‍Year 3 Revenue: $1M
    ‍Year 5 Revenue: $5M
  • Key Financial Metrics:

    ‍Customer Acquisition Cost (CAC): $2,000
    ‍Lifetime Value (LTV): $30,000
    ‍Gross Margin: $1,200 per treatment
    ‍Net Profit Margin: 20%

Team

  • A multidisciplinary team of biotech innovators, medical experts, and AI specialists leading the next evolution in cancer treatment.
  • Founder & CEO – Experienced entrepreneur with a background in fintech, biotech, and marketing. Passionate about transforming oncology care through AI-driven, non-invasive therapies.
  • Investment & Strategy Lead – Specializes in investment banking and venture capital, with a background in M&A across global financial hubs.
  • Chief Medical Advisor – A leading expert in AI-powered diagnostics, specializing in computer vision machine learning for precision medicine.
  • Future Hiring Plans – Expanding to 10 new team members, focusing on clinical research, AI development, and regulatory compliance.

Competitive Edge

  • Non-invasive, pain-free treatment with a 70% success rate.
  • AI-driven personalization of treatments for increased effectiveness.
  • Significantly lower cost compared to chemotherapy and radiation.
  • Scalable telehealth model enabling remote cancer treatment access.
  • Strong potential for integration with future precision medicine technologies (CRISPR, genomics, liquid biopsy).

Risks & Mitigation

  • Market Competition: Position as a pioneer in AI-powered, non-invasive cancer treatment.
  • Regulatory Uncertainty: Early engagement with healthcare regulators for compliance.
  • Financial Risks: Multi-channel fundraising approach, including grants, partnerships, and equity investment.
  • Operational Risks: Partnering with leading hospitals and research institutions to scale efficiently.

Funding Requirements

  • Funding Required: $2M
  • Use of Funds:

    $250K – Product development (AI tool, treatment refinement)
    ‍$250K – Marketing and sales efforts
    ‍$400K – Key hires in medical and AI teams
    ‍$1.1M – Technology, and training
  • Projected Runway with Funding: 3 years

Exit Strategy

  • IPO – Going public to scale treatment accessibility and AI expansion.
  • Acquisition – Potential buyers include major pharmaceutical and biotech companies seeking next-gen cancer therapies.
  • Strategic Partnerships – Licensing deals with oncology research institutions and hospital networks.
  • Projected Exit Timeline: 5 years

Why Invest?

  • Massive Market Potential: $280B+ cancer treatment industry, growing at 9.7% CAGR.
  • Disruptive Technology: AI-driven, non-invasive cancer treatment with a 70% success rate.
  • Strong Competitive Advantage: Faster, more affordable, and pain-free alternative to traditional cancer therapies.
  • Validated Early Traction: Positive patient trial feedback and first hospital partnership secured.
  • Scalable & High-Growth Model: Telemedicine and AI-driven solutions enable rapid market expansion.
  • High Exit Potential: IPO or acquisition within 5 years.

Pitch Deck

View the deck through the link below—while some unique identifiers have been removed, it still offers a great overview. For access to detailed investor materials, please reach out to us, as full decks are only shared upon request to maintain confidentiality and exclusivity.

View Pitch Deck

Interested in the startup?

Let us know, if you'd like to request more information about the company, or if you'd like to hear a great pitch first.

Investor Interest Form